usatoday24
The success of drugs such as Ozempic, Wegovy either Zepbound He has unleashed a career in pharmaceutical laboratories around the world. These are based on compounds originally devised as treatments against type 2 diabetes but have devastated as weight loss formulas.
Orforglipron. The American pharmaceutical has successfully overcome The third phase of your clinical trials. As the company explains, this formula is the first drug in its class to pass this test, the first oral agonist of LPG-1 receptors of a small molecule that can be consumed without restrictions on water or food consumption.
GLP-1 agonist. Orforglipron, such as the semaglutida on which Ozempic and Wegovy are based, is an agonist of the peptide receptors similar to glucagon-1 (LPG-1), that is, it is based on a molecule that emulates this hormone that produces our body. LPG-1 is a peptide that is released in our body when we eat and transmits the message that we have eaten two recipients for two different purposes.
On the one hand, this message transmits to the pancreas so that it begins to segregate the insulin that our body will require to metabolize the sugar consumed. Hence, this type of compound is used in patients with type 2 diabetes. The second message is transmitted to the brain, which interprets it as a feeling of satiety.
Achieve The Achieve-1 trial, framed in the Achieve program, was carried out with the objective of evaluating the safety and efficacy of Orforglipron, contrasting its administration with the administration of a placebo in adults with type 2 diabetes and inappropriate glycemic control. The experiment also studied different dosages in the participants.
The responsible team observed that, after 40 weeks, the average blood glucose levels They differ satisfactorily between the experimental group and the control group. The study also showed a reduction in the body mass of those who consumed the drug.
“It is a pleasure to see that our last medicine (…) meets our expectations of safety and tolerability, glycemic control and weight loss, and we are waiting for additional readings of the data throughout this year,” indicated in a press release David A. Ricks, President and CEO of Lilly. The details of these clinical trials will be presented in the scientific sessions of the ADA (American Diabetes Association), as well as in a magazine in an article reviewed by pairs.
Adverse effects. One of the most important purposes of clinical trials is the detection of possible adverse effects with which to evaluate whether the drug involves any important risk and if its possible adverse effects are compensated or not by their medical benefit. The side effects detected are not very different from those already found in treatments such as Ozempic.
The most common adverse effects were gastrointestinal and “generally between soft and moderate in severity”: diarrhea, nausea, dyspepsia vomiting (indigestion or empacho) or constipation. Those responsible for the study indicated that no hepatic security problems were detected.
A key step. Overcoming this third phase of clinical trials is a fundamental step for the arrival of the drug to pharmacies but does not imply its immediate approval. The final green light will have to give it the regulatory agencies of pharmacological products such as the US FDA or the European EMA.
Image | JESHOTS.com
GIPHY App Key not set. Please check settings